Glass House Brands (GLAS) Share-based Compensation (2020 - 2026)
Glass House Brands' (GLAS) quarterly Share-based Compensation came in at $4.5 million in Q1 2026, up 114.87% year-on-year from $2.1 million in Q1 2025, and up 5.83% on a QoQ basis from $4.3 million in Q4 2025.
Glass House Brands (GLAS) Share-based Compensation (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.
- On a quarterly basis, Share-based Compensation rose 114.87% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 32.6% increase from a year earlier, with the FY2025 full-year figure at $13.4 million, up 2.32% from the prior year.
- Share-based Compensation for Q1 2026 stood at $4.5 million, up from $4.3 million in the prior quarter.
- Over the last five years, Share-based Compensation for GLAS reached as high as $4.5 million in Q1 2026 and fell as low as $1.5 million in Q2 2023.
- Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.9 million in 2024.
- Across the five-year window, Share-based Compensation soared 323.63% in 2022 and plunged 56.12% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $3.8 million in 2022, then plunged by 49.36% to $1.9 million in 2023, then surged by 70.66% to $3.3 million in 2024, then jumped by 31.18% to $4.3 million in 2025, then gained by 5.83% to $4.5 million in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $4.5 million in Q1 2026, $4.3 million in Q4 2025, and $4.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 58.30 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn | 4.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.52 Mn |
| Mar 31, 2026 | 4.52 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Dec 31, 2025 | 4.27 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.08 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.94 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Mar 31, 2025 | 2.11 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Sep 30, 2024 | 2.95 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Jun 30, 2024 | 3.62 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Mar 31, 2024 | 3.27 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Dec 31, 2023 | 1.91 Mn |